In this study, Lacticaseibacillus rhamnosus LRa05 was selected as test preparations to observe the clinical efficacy in the intervention trial of combined antibiotic therapy, and to evaluate its effects on the cure rate, recurrence rate and vaginal microbiota of patients with bacterial vaginitis.
18 to 65 years old, sexual activity, premenopausal women;
Nugent score for diagnosing BV ≥7;
Signed informed consent.
Mixed vaginitis, such as vulvovaginal candidiasis (VVC), Trichomonas vaginalis (TV) infection, Chlamydia trachomatis (CT) infection or gonococcal vaginitis;
history of systemic organic disease or psychiatric illness;
Planning pregnancy, breastfeeding, menstruation;
within 5 days of the onset of the disease, any antibiotics have been used;
Parallel
Probiotic
Dietary supplementThe experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
Placebo
Dietary supplementThe experimental phase of this study will last 8 weeks and each subject will receive 4 follow-up visits (week 0, week 4, week 8, week 20).
Cure rate of bacterial vaginosis
The Nugent score of ≤3 is considered successful in bacterial vaginosis treatment
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
